

Attorney's Docket No. 033339/317269

IN THE UNITED STATES DESIGNATED OFFICE (DO/US)

In re: Drevet

Attn: DO/US

International Appl. No.: PCT/FR05/00795

International Filing Date: 04/01/2005

For: STABILIZED TAT ANTIGEN AND THE USE THEREOF FOR ANTI-HIV
VACCINATION

Mail Stop PCT
Commissioner for Patents
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

The patents listed on the attached PTO-1449 were cited in the International Search Report of corresponding International Application No. PCT/FR05/00795. A copy of the Search Report and documents cited therein are enclosed for the Examiner's convenience.

The Examiner may wish to consider the notations on the Search Report itself regarding the relevance of each item. It is requested that the Examiner consider these references and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

Respectfully submitted,

/Raymond O. Linker, Jr./

Raymond O. Linker, Jr.
Registration No. 26,419

ALSTON & BIRD LLP

Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Charlotte Office (704) 444-1000
Fax Charlotte Office (704) 444-1111
Customer No. 00826
LEGAL02/30099976v1

ELECTRONICALLY FILED USING THE EFS-WEB ELECTRONIC FILING SYSTEM OF THE UNITED STATES PATENT & TRADEMARK OFFICE ON SEPTEMBER 28, 2006.

Substitute for form 1449/PTO (Revised 07/2005) INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known		
				Application Number	TO BE ASSIGNED	
				Filing Date	Concurrently Herewith	
				First Named Inventor	Drevet, et al.	
				Group Art Unit		
Examiner Name						
Sheet	1	of	2	Attorney Docket Number	033339/317269	
FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
	1	WO 01/54719 A	08/02/2001	Smithkline Beecham		
	2	WO 03/011334 A	02/13/2003	Glaxosmithkline Biologicals S.A.		
	3	WO 00/61067 A	10/19/2000	Loret		
	4	WO 99/02185 A	01/21/1999	Thymon LLC		
	5	WO 03/057885 A	07/17/2003	Biomerieux SA		
	6	WO 03/54006 A	07/03/2003	Klein		
	7	WO 01/82944 A	11/08/2001	Thymon LLC		
	8	WO 2004/024173 A	03/25/2004	Creabilis Therapeutics SRL		
OTHER DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				English Language Translation Attached
	9	CHANG HSIAO C. et al., "HIV-1 Tat protein exists from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparin sulfate proteoglycans through its basic region", AIDS, Vol. 11, No. 12, 1997, pp. 1421-1431.				
	10	NOONAN DOUGLAS M et al., "Identification of immunodominant epitopes in inactivated Tat-vaccinated healthy and HIV-1-infected volunteers", JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (1999), 1 May 2003, Vol. 33, No. 1, pp. 47-55.				
	11	PAUZA C. DAVID et al., "Vaccination with Tat toxoid attenuates disease in simian/HIV-challenged macaques", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, March 28, 2000, Vol. 97, No. 7, pp. 3515-3519.				
	12	CAFARO A. et al., "Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine" NATURE MEDICINE, NATURE PUBLISHING CO., Vol. 5, No. 6, June 1999, pp. 643-650.				
	13	ALBINI ADRIANA et al., "HIV-tat protein as a heparin-binding angiogenic growth factor", ONCOGENE, Vol. 12, No. 2, 1996, pp. 289-297.				
Examiner Signature				Date Considered		

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 07/2005) INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	TO BE ASSIGNED
				Filing Date	Concurrently Herewith
				First Named Inventor	Drevet, et al.
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	033339/317269
	14	HAKANSSON SUSANNA et al., "Structural and dynamic properties of the HIV-1 tat transduction domain in the free and heparin-bound states, BIOCHEMISTRY, Vol. 42, No. 30, 08/05/2003, pp. 8999-9006.			
	15	WATSON KEITH et al., "Interaction of the transactivating protein HIV-1 tat with sulphated polysaccharides", BIOCHEMICAL PHARMACOLOGY, Vol. 57, No. 7, April 1, 1999, pp. 775-783			
	16	RUSNATI MARCO et al., "The basic domain in HIV-1 Tat protein as a target for polysulfonated heparin-mimicking extracellular Tat antagonists", JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 273, No. 26, June 26, 1998, pp. 16027-16037.			
	17	MISUMI SHOGO et al., "Zn ²⁺ binding to cysteine-rich domain of extracellular human immunodeficiency virus type 1 Tat protein is associated with Tat protein-induced apoptosis", AIDS RESEARCH AND HUMAN RETROVIRUSES, Vol. 20, No. 3, March 2004, pp. 297-304.			
	18	MARCHIO SERENA et al., "Cell surface-associated Tat modulates HIV-1 infection and spreading through a specific interaction with gp120 viral envelope protein", BLOOD, Vol. 105, No. 7, April 2005, pp. 2802-2811.			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.